MA52946B1 - Composés - Google Patents

Composés

Info

Publication number
MA52946B1
MA52946B1 MA52946A MA52946A MA52946B1 MA 52946 B1 MA52946 B1 MA 52946B1 MA 52946 A MA52946 A MA 52946A MA 52946 A MA52946 A MA 52946A MA 52946 B1 MA52946 B1 MA 52946B1
Authority
MA
Morocco
Prior art keywords
formula
compounds
hydrogen
methods
compositions
Prior art date
Application number
MA52946A
Other languages
English (en)
French (fr)
Other versions
MA52946A (fr
Inventor
Pamela Brown
Michael Dawson
Mona Simonovic
Steven Boakes
Esther Duperchy
Dean Rivers
Roy Lester
Scott Coleman
Original Assignee
Spero Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spero Therapeutics Inc filed Critical Spero Therapeutics Inc
Publication of MA52946A publication Critical patent/MA52946A/fr
Publication of MA52946B1 publication Critical patent/MA52946B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA52946A 2018-06-25 2019-06-25 Composés MA52946B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862689602P 2018-06-25 2018-06-25
PCT/EP2019/066819 WO2020002325A1 (en) 2018-06-25 2019-06-25 Compounds

Publications (2)

Publication Number Publication Date
MA52946A MA52946A (fr) 2021-04-28
MA52946B1 true MA52946B1 (fr) 2024-03-29

Family

ID=67107423

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52946A MA52946B1 (fr) 2018-06-25 2019-06-25 Composés

Country Status (31)

Country Link
US (3) US11459357B2 (enExample)
EP (2) EP3810633B1 (enExample)
JP (2) JP7488774B2 (enExample)
KR (1) KR20210054500A (enExample)
CN (2) CN118878638A (enExample)
AR (1) AR116663A1 (enExample)
AU (2) AU2019294261B2 (enExample)
BR (1) BR112020026663A2 (enExample)
CA (1) CA3103158A1 (enExample)
CO (1) CO2020016080A2 (enExample)
DK (1) DK3810633T3 (enExample)
EA (1) EA202092819A1 (enExample)
ES (1) ES2971732T3 (enExample)
FI (1) FI3810633T3 (enExample)
HR (1) HRP20240028T1 (enExample)
HU (1) HUE065134T2 (enExample)
IL (2) IL279620B2 (enExample)
LT (1) LT3810633T (enExample)
MA (1) MA52946B1 (enExample)
MD (1) MD3810633T2 (enExample)
MX (1) MX2020013811A (enExample)
PH (1) PH12020552240A1 (enExample)
PL (1) PL3810633T3 (enExample)
PT (1) PT3810633T (enExample)
RS (1) RS65128B1 (enExample)
SG (1) SG11202012747VA (enExample)
SI (1) SI3810633T1 (enExample)
TW (2) TWI851584B (enExample)
UA (1) UA128162C2 (enExample)
WO (1) WO2020002325A1 (enExample)
ZA (1) ZA202301937B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108699A (zh) 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
DK3810633T3 (da) * 2018-06-25 2024-01-15 Spero Therapeutics Inc Forbindelser
TW202233649A (zh) 2020-11-06 2022-09-01 美商斯佩羅治療學股份有限公司 化合物
WO2022262823A1 (zh) * 2021-06-18 2022-12-22 华南理工大学 活性氧自由基响应的多粘菌素前药化合物及其应用
CN120574287B (zh) * 2025-06-10 2026-07-03 中国药科大学 一种抗菌肽、组合物及应用
CN121159640A (zh) * 2025-07-24 2025-12-19 中国药科大学 一种抗菌肽、药物组合物及应用
CN120699105B (zh) * 2025-08-19 2025-11-21 中国药科大学 一种氘代抗菌肽及其组合物和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
AU7753787A (en) 1986-08-06 1988-02-24 Jean-Luc Fauchere Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
TW274552B (enExample) 1992-05-26 1996-04-21 Hoechst Ag
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
JP2007507512A (ja) 2003-09-30 2007-03-29 コーヒ コーポレーション 熱傷を治療するための組成物および方法
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
BRPI0715095B8 (pt) 2006-08-11 2021-05-25 Northern Antibiotics Oy derivado de polimixina da fórmula geral (i); produto de combinação; composição farmacêutica; método para se sensibilizar bactérias gram-negativas a um agente antibacteriano; método para o desenvolvimento de antibióticos; método para a redução da toxicidade de polimixinas, octapeptinas naturais e seus derivados durante a aplicação das mesmas no tratamento de infecções em um indivíduo; método para melhorar as propriedades farmacocinéticas, de polimixinas, octapeptinas naturais e seus derivados; método para a sensibilização de bactérias gram-negativas clinicamente importantes a um complemento de mecanismo de defesa presente no soro; uso de um derivado; e processo para a preparação de um derivado de polimixina da fórmula (i).
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
FI20085469A0 (fi) 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
ES2334547B1 (es) 2008-09-10 2010-12-03 Universidad De Barcelona Compuestos peptidicos antibacterianos.
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (en) 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
MX355217B (es) 2011-11-18 2018-04-10 New Pharma Licence Holdings Ltd Derivados de polimixina.
HUE059544T2 (hu) 2013-05-22 2022-11-28 Spero Therapeutics Inc Polimixin-származékok és ezek alkalmazása kombinációs terápiában különbözõ antibiotikumokkal
KR20160135739A (ko) * 2014-03-11 2016-11-28 뉴 파마 라이센스 홀딩스 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
US10047126B2 (en) 2014-04-01 2018-08-14 Monash University Polymyxin derivatives as antimicrobial compounds
CN107108699A (zh) 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
BR112017010888A2 (pt) * 2014-12-17 2018-02-27 Hoffmann La Roche método para produzir um produto de conjugação enzimática de três polipeptídeos
WO2016166103A1 (en) * 2015-04-13 2016-10-20 Xellia Pharmaceuticals Aps Polymyxin derivatives
JP7367950B2 (ja) * 2015-09-29 2023-10-24 モナッシュ ユニバーシティ 抗菌性ポリミキシン誘導体化合物
US10428122B2 (en) * 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
DK3810633T3 (da) * 2018-06-25 2024-01-15 Spero Therapeutics Inc Forbindelser
WO2020014501A1 (en) 2018-07-11 2020-01-16 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections

Also Published As

Publication number Publication date
CN118878638A (zh) 2024-11-01
MA52946A (fr) 2021-04-28
IL279620B1 (en) 2025-11-01
RS65128B1 (sr) 2024-02-29
WO2020002325A1 (en) 2020-01-02
US20230012121A1 (en) 2023-01-12
EA202092819A1 (ru) 2021-05-21
MX2020013811A (es) 2021-03-09
NZ771833A (en) 2024-09-27
JP2021528449A (ja) 2021-10-21
MD3810633T2 (ro) 2024-05-31
CA3103158A1 (en) 2020-01-02
HRP20240028T1 (hr) 2024-03-29
IL279620B2 (en) 2026-03-01
TWI851584B (zh) 2024-08-11
LT3810633T (lt) 2024-01-10
EP4316504A2 (en) 2024-02-07
IL323560A (en) 2025-11-01
US20260103491A1 (en) 2026-04-16
BR112020026663A2 (pt) 2021-03-23
CN112789287B (zh) 2024-06-21
US20210246169A1 (en) 2021-08-12
ZA202301937B (en) 2023-09-27
TW202446783A (zh) 2024-12-01
HUE065134T2 (hu) 2024-05-28
FI3810633T3 (fi) 2024-02-09
AU2019294261A1 (en) 2021-02-04
SI3810633T1 (sl) 2024-04-30
CO2020016080A2 (es) 2021-01-18
PH12020552240A1 (en) 2021-08-16
EP3810633B1 (en) 2023-12-13
AU2024203362A1 (en) 2024-06-06
AR116663A1 (es) 2021-06-02
JP2024109664A (ja) 2024-08-14
DK3810633T3 (da) 2024-01-15
US11459357B2 (en) 2022-10-04
EP3810633A1 (en) 2021-04-28
ES2971732T3 (es) 2024-06-06
US12528837B2 (en) 2026-01-20
TW202019949A (zh) 2020-06-01
AU2019294261B2 (en) 2024-02-29
PT3810633T (pt) 2024-02-19
EP4316504A3 (en) 2024-04-17
SG11202012747VA (en) 2021-01-28
PL3810633T3 (pl) 2024-04-08
IL279620A (en) 2021-03-01
JP7488774B2 (ja) 2024-05-22
CN112789287A (zh) 2021-05-11
UA128162C2 (uk) 2024-04-24
KR20210054500A (ko) 2021-05-13

Similar Documents

Publication Publication Date Title
MA51530B1 (fr) Composés cycliques fondus
MA45020B1 (fr) Dérivés sulfonamides aromatiques
MA51620B1 (fr) Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques
MA52360B1 (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines
MA63032B1 (fr) Composés contenant du nitrile pour utilisation comme médicaments
MA65131A1 (fr) Utilisation d'un inhibiteur d'ezh2 dans la préparation d'un médicament pour le traitement d'un lymphome à cellules t
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
EA202092819A1 (ru) Соединения
MA32965B1 (fr) Derives de sulfonamides
CO2020004087A2 (es) Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas
MA35601B1 (fr) Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
MA34308B1 (fr) Triazolopyridines substituées
MA29335B1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA40523A (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA41389A1 (fr) Utilisation de sulfones tricycliques en tant que modulateurs de rory
MA49127B1 (fr) Dérivés d'indole n-substitués
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA62917A1 (fr) Composés de lactivicine, leur préparation et leur utilisation en tant qu'agents antibactériens
MA66991A1 (fr) Composés d'administration de gamma-hydroxybutyrate et leurs procédés de préparation et méthodes d'utilisation